Cerebrospinal fluid interleukin-6 concentration in patients with purulent, bacterial meningitis - own observations. 2014

Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
Department of Infectious Diseases in Bytom Medical University of Silesia in Katowice.

OBJECTIVE This study aimed at evaluating the usefulness of determining cerebrospinal fluid (CSF) interleukin-6 (IL-6) concentration in adults with purulent, bacterial meningoencephalitis. METHODS A study group consisted of 16 patients hospitalized in the Department of Infectious Diseases of the Medical University of Silesia in Bytom in 2008 - 2012 due to purulent, bacterial meningoencephalitis. All of them were classified into two groups based on clinical severity, assessed on admission: group I - severe condition, group II - moderately severe or mild condition. CSF IL-6 concentration was measured in all patients on the first day of hospitalization. RESULTS Mean concentrations of IL-6 in CSF were assessed at 391.54 pg/mL and 110.51 pg/mL in patients in severe (group I) and moderately severe or mild condition (group II), respectively. Differences between CSF mean concentrations of this cytokine in both groups were statistically significant (p<0.01). No correlations between CSF IL-6 concentrations and other CSF inflammatory parameters were determined. Control testing performed in 5 patients of group I revealed only slight decrease of CSF IL-6 concentration in fatal cases. In case of patients who recovered from disease, IL-6 concentration in CSF was evidently decreased compared to its initial value. CONCLUSIONS Results suggest the usefulness of determining CSF interleukin-6 concentration to estimate inflammation intensity in the subarachnoid space, and indirectly, patient's clinical severity. IL-6 concentration may be also of prognostic importance in purulent, bacterial meningoencephalitis.

UI MeSH Term Description Entries
D008297 Male Males
D008590 Meningoencephalitis An inflammatory process involving the brain (ENCEPHALITIS) and meninges (MENINGITIS), most often produced by pathogenic organisms which invade the central nervous system, and occasionally by toxins, autoimmune disorders, and other conditions. Cerebromeningitis,Encephalomeningitis,Cerebromeningitides,Encephalomeningitides,Meningoencephalitides
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon

Related Publications

Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
January 2013, Przeglad epidemiologiczny,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
January 2012, Przeglad epidemiologiczny,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
November 1994, The Pediatric infectious disease journal,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
January 2005, Przeglad epidemiologiczny,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
June 1951, The Journal of clinical investigation,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
February 1992, Acta neurologica,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
January 1981, Scandinavian journal of infectious diseases,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
January 1999, Neurologia i neurochirurgia polska,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
March 2005, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
Lucjan Kępa, and Barbara Oczko-Grzesik, and Anna Boroń-Kaczmarska
December 1987, The Medical journal of Malaysia,
Copied contents to your clipboard!